Patents Assigned to MyMD Pharmaceuticals, Inc.
  • Patent number: 11938126
    Abstract: In some aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of diseases of the visual system.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: March 26, 2024
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11629355
    Abstract: Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: April 18, 2023
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10918633
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: February 16, 2021
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10835523
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: November 17, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10806728
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 20, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10786493
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 29, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10722506
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: July 28, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10588899
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: March 17, 2020
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10517856
    Abstract: In one aspect, a method of altering programmed cell death includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine is administered to treat a wound, hemochromatosis, traumatic brain injury, or disorders associated with chronic oxidative stress. In other aspects, isomyosmine is administered to increase blood oxygen saturation levels.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 31, 2019
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10471052
    Abstract: A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of addiction to heroin (diacetylmorphine), cocaine, opioids, methadone, d-methamphetamine, barbiturates, alcohol, benzodiazepines, amphetamines, or buprenorphine. The isomyosmine, along with optional additional therapeutic agent(s), may be administered in a capsule, tablet, or lozenge.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: November 12, 2019
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10213438
    Abstract: Alkaloid compounds described herein are useful for treating disorders associated with monoamine oxidase (MAO) activity, such as depression, pain, smoking cessation, and substance addictions, and/or for treating disorders associated with chronic or low-level inflammation. In some examples, compounds are effective for treating cancers, autoimmune disorders, and other disorders associated with inducible nitric oxide synthase (iNOS).
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 26, 2019
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Publication number: 20180042909
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Application
    Filed: March 31, 2016
    Publication date: February 15, 2018
    Applicant: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 9884055
    Abstract: A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of affecting smoking substitution, eliminating cravings for tobacco and nicotine, or transitioning individuals away from smoking or the use of other tobacco products. In some examples, the therapeutic agent(s) are administered in a capsule, tablet, or lozenge. In other examples, the therapeutic agent(s) are administered via a chewing gum, inhalation spray, e-cigarette, nasal spray, or transdermal patch.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 6, 2018
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams